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1. Introduction 
 
Atherosclerotic vascular disease is on the way being the major cause of morbidity 
and mortality worldwide (Lloyd-Jones et al., 2009). Considering this circumstance, 
every effort in understanding the players and contributors in this disease is of 
importance. A pathological characteristic of atherosclerosis is foam cell formation 
rooting in cholesterol accumulation in macrophages within the arterial wall (for review 
see: Van Eck et al., 2005). Besides LDL (low density lipoprotein) and oxidized lipids, 
also VLDL plays a role in atherogenesis. The atherogenic form of very low density 
lipoproteins (VLDLs), the so called beta-VLDL (ß-VLDL) particles is widely-used as a 
model for chylomicron remnants. The particles accumulate in the plasma of patients 
with type III hyperlipoproteinemia and in cholesterol-fed animals (Mahley et al., 1977; 
Brewer et al., 1983). ß-VLDL was shown to induce cholesteryl ester accumulation in 
macrophages leading to foam cell formation (Bersot et al., 1983; Goldstein et al., 
1980). Recently, scavenger receptor, class B, type I (SR-BI) has been linked to ß-
VLDL uptake (Van Eck et al., 2008), in addition to its well-established role in high 
density lipoprotein (HDL) metabolism. 
The aim of the present study was to examine the role of SR-BI in ß-VLDL metabolism 
in tissue culture. Although the LDL-receptor pathway appears to be of major 
importance for ß-VLDL uptake, it is of interest to characterize the alternative route via 
SR-BI. We used two different sets of cells. On the one hand we examined cells which 
express normal levels of the LDL-receptor, namely the human hepatoma cell line 
HepG2 and Chinese Hamster Ovarian cells (CHO). On the other hand we analyzed 
CHO cells that lack any functional LDL-receptor named ldlA7, as well as ldlA7 cells 
overexpressing SR-BI (ldlA7-SRBI). In order to charaterize the function of SR-BI in ß-
VLDL processing, uptake and degradation experiments were performed using 
iodinated ß-VLDL. For a more detailed characterization of ß-VLDL binding, 
competition experiments were performed using a 10-fold excess of unlabeled 
lipoproteins. SR-BI knockdown in HepG2 cells was another tool in identifying the 
receptor´s importance in ß-VLDL cell association. Further, the effect of ß-VLDL 
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feeding on the cellular lipid pool was assessed using HPLC and the Oil Red O 
method.  
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2. Status of Research 
2.1 Lipoprotein metabolism 
 
Lipoproteins are required to transport cholesterol and triglycerides in the blood. In the 
intestine, dietary fat is packaged into chylomicrons, which are large triglyceride-rich 
lipoproteins (Fig.1). Chylomicrons are transported to peripheral tissues where the 
triglycerides are hydrolyzed by the lipoprotein lipase (LPL) resulting in free fatty acids 
entering these tissues (mainly in heart, skeletal muscle and adipose tissue). The 
chylomicron remnants are then cleared by the liver. The liver loads apolipoprotein-B 
(apo-B) with lipids and secretes very low density lipoproteins (VLDLs), which form 
low density lipoproteins (LDLs) after lipolysis by LPL. LDLs are taken up by the liver 
via binding to recognition sites like the LDL-receptor. High density lipoproteins 
(HDLs) are assembled by the intestine and the liver through lipid-free apo-AI which 
assimilates cholesterol from these organs through ATP-binding cassette transporter 
A1 (ABCA1) forming nascent HDLs. In peripheral tissues nascent and mature HDLs 
promote cholesterol efflux via ABCA1 and ATP-binding cassette transporter G1 
(ABCG1). Mature HDLs emerge from the esterification of free cholesterol by lecithin 
cholesterol acyltransferase (LCAT). HDLs transport cholesterol to the liver, a process 
which is known as reverse cholesterol transport, involving SR-BI (Rader et al., 2003). 
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Figure 1: Lipoprotein metabolism (Rader et al., 2008). 
 
2.2 Atherosclerosis 
2.2.1 Epidemiology 
 
Atherosclerosis is the underlying cause of most clinical cardiovascular disease (CVD) 
events. CVD accounted for 35.3% of all deaths in 2005 in the United States. 
Atherothrombotic diseases are associated with the leading causes of death 
worldwide, and the prevalence is increasing. They are expected to be the main cause 
of death in 2020 (Lloyd-Jones et al., 2009). Between 1990 and 2020, the percentage 
of deaths from CVD is projected to increase from 28.9% to 36.3%. This alarming 
progression is associated with two trends in developing countries. First, the 
displacement of malnutrition and infectious disease as primary cause of death, 
leading to an aging of the population. Second, notably increases in cigarette 
smoking, one established risk factor of atherosclerosis among others like elevated 
cholesterol levels or hypertension. Different factors such as obesity, physical 
inactivity or diabetes are also suggested to be associated with increased risks of 
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CVD. Besides that, several new atherogenic risk factors, such as homocysteine, are 
discussed (Hennekens, 1998).  
2.2.2 Atherogenesis 
 
Atherosclerotic lesion development, the hallmark of atherosclerosis, ist the initial step 
contributing to atherogenesis (Fig. 2). Atherosclerotic lesions are thickenings of the 
intima, the innermost layer of the arteries. Cells (inflammatory and immune cells, 
endothelial and smooth muscle cells), connective-tissue elements and lipids are the 
major component of those thickenings. The earliest atherosclerotic lesion, the so-
called fatty streak, results from an accumulation of lipid-loaded cells (Hansson, 
2005). 
 
These changes of the arterial wall are followed by endothelial activation. 
Hypercholesterolemia leads to an infiltration of excess LDL in the intima, which 
causes an inflammatory response. Oxidation or other changes of LDL lead to an 
activation of endothelial cells. The first response to this activation is platelet 
adhesion, followed by attachment of other blood cells. The intima then releases 
chemokines that induce the migration of cells such as monocytes into the 
subendothelial space (Hansson, 2005) 
 
This migration of cells leads to a further characteristic of atherogenesis, namely foam 
cell formation. Monocytes that enter the plaque differentiate into macrophages, 
stimulated by growth factors, such as the macrophage colony-stimulating factor (M-
CSF). The focal areas of the arterial walls become populated with differentiated 
macrophages. The macrophages internalize subendothelial lipoproteins and they 
accumulate intracellular cholesterol in cytosolic lipid droplets. The lipoproteins enter 
the subendothelium likely by transcytosis through endothelial cells or through 
transient gaps between endothelial cells (Tabas, 2000; Hansson 2005). This process 
involves the LDL-receptor, caveolin-1, ABCA1 and ABCG1 or SR-BI (von Eckardstein 
et al., 2009). The major storage form of cholesterol is primarily cholesteryl esters. At 
6 
 
this stage, the macrophages are termed foam cells. Especially in advanced 
atherosclerotic lesions, accumulation of free cholesterol occurs (Tabas, 2000; 
Hansson 2005). 
 
In addition to foam cell formation, which has an impact on early atherogenesis but 
also on late lesion development, inflammation plays a key role in atherosclerosis. 
Immune cells within the atherosclerotic plaque produce inflammatory cytokines 
(interferon-γ, interleukin-1 and tumor necrosis factor). This activation in the cytokine 
cascade results in increased levels of interleukin-6 and C-reactive protein. 
Furthermore, antiinflammatory cytokines such as interleukin-10 and transforming 
growth factor ß (TGF-ß) are involved. 
The progression of atherosclerosis is mainly influenced by the equilibration between 
pro- and antiinflammatory processes (Hansson, 2005). 
 
 
Figure 2: Progression of atherosclerosis. A lesion begins as a fatty streak (a) and 
can develop into an intermediate lesion (b), and then into a lesion that is vulnerable 
to rupture (c) and, finally, into an advanced obstructive lesion (d) (Rader et al., 2008). 
 
2.3 Cholesterol homeostasis 
 
Cellular cholesterol homeostasis can be maintained by three possible mechanisms: 
cholesterol synthesis, uptake and efflux. 
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2.3.1 Intracellular cholesterol transport and regulation of the cellular 
cholesterol content 
 
In the endoplasmic reticulum (ER), cholesterol is synthesized by 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase. Another source of cholesterol is 
the internalization of lipoprotein particles. Cholesteryl esters, delivered by apo-B/E 
containing lipoproteins via the LDL-receptor, are hydrolyzed in late endosomes and 
lysosomes. Free cholesterol is then exported to other organelles (Maxfield et al., 
2002).  
Cellular cholesterol levels are tightly regulated by the LDL-receptor and HMG-CoA 
reductase. The storage of cholesterol in its cholesteryl ester form is controlled by the 
esterifying enzyme acyl CoA:cholesterol acyltransferase (ACAT). Cholesterol 
depleted cells express high levels of the LDL-receptor and HMG-CoA reductase but 
low levels of ACAT. When cellular cholesterol levels increase, the process is 
reversed, activating ACAT and lowering LDL-receptor and HMG-CoA reductase 
activity (Brown et al., 1986).  
The expression of the LDL-receptor and enzymes involved in cholesterol 
biosynthesis is regulated by a family of transcription factors, the so called sterol 
responsive element binding proteins (SREBPs). SREBPs are membrane-bound 
transcription factors that modulate the transcription of enzymes involved in 
cholesterol biosynthesis. SREBPs need to be released from the ER-membrane by 
proteases to function. In sterol-depleted cells, the transcription factors are released 
and enhance expression of genes encoding enzymes such as HMG-CoA reductase 
and the transcription of the LDL-receptor. An increasing cellular sterol content blocks 
the release of SREBPs leading to a decline in the transcription of the target genes 
(Brown et al., 1999). 
 
2.3.2 Reverse cholesterol transport and cholesterol efflux 
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The transport of cholesterol from extrahepatic tissues, including arterial wall 
macrophages, to the liver for excretion as free cholesterol and bile acids is described 
as reverse cholesterol transport (RCT) (Ohashi et al., 2005). This removal of 
lipoprotein derived excessive peripheral cholesterol is of major importance in the 
prevention of atherosclerosis. The atheroprotective function of HDL is mostly 
ascribed to its participation in RCT. 
HDL is also involved in the initial step of RCT referred to as cholesterol efflux. This is 
a process in which cholesterol is transferred to HDL from peripheral cells. Several 
receptors mediate the flux of cholesterol to lipoproteins such as ABCA1, ABCG1 and 
SR-BI (for review see: Tall et al., 2008). SR-BI mediates this bidirectional transport of 
unesterified cholesterol between lipoproteins and cells in tissue culture. In this 
context, a correlation of SR-BI expression and cholesterol efflux rates was reported 
(Ji et al., 1997). 
2.3.3 Retroendocytosis 
 
The retroendocytosis mechanism involves receptor binding, endocytosis and 
resecretion of the lipoprotein particle. HDL retroendocytosis was first described by 
Bierman et al. (1974) in rat aortic smooth muscle cells. In macrophages HDL was 
internalized through receptor binding to a non-lysosomal compartment followed by 
secretion (Schmitz et al., 1985). Further studies by DeLamatre et al. (1990) provided 
similar results in rat hepatoma cells. Resecreted HDL particles were depleted of 
cholesteryl esters and the size distribution was modified, indicating lipoprotein 
catabolism and remodelling. HDL retroendocytosis even occured in the presence of 
inhibitors of intracellular cholesterol transport, such as monensin (Pagler et al., 
2007). 
 
2.3.4 Selective cholesteryl ester uptake 
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Selective uptake is a process in which cholesteryl esters are transferred to cells 
without degradation of the lipoprotein particle (Glass et al., 1983). This is in contrast 
to the LDL-receptor pathway where the lipoproteins are endocytosed through clathrin 
coated pits and degraded. Selective uptake is thought to be a two-step mechanism: 
an initial lipoprotein binding step is followed by a lipid transfer step (Trigatti et al., 
2003). The cholesteryl esters are first transported to a reversible plasma membrane 
pool and further transferred to an irreversible intracellular compartment (Rinninger et 
al., 1993). 
SR-BI was shown to mediate selective cholesteryl ester uptake from HDL and is 
highly expressed in liver and steroidogenic tissues, where this form of uptake ist 
important (Acton et al., 1996).  
Further studies found increased HDL cholesterol levels in SR-BI knockout mice, likely 
due to decreased selective cholesterol uptake. These results suggest an important 
role of SR-BI in regulating plasma lipoprotein cholesterol levels (Rigotti et al., 1997). 
Fluourescently labeled HDL (DiI-HDL) was used to assess the cellular distribution of 
HDL derived lipid. LDL-receptor positive CHO cells showed a punctuate staining 
pattern, typical for receptor-mediated endocytosis, whereas LDL-receptor lacking but 
SR-BI overexpressing cells exhibited a completely different diffuse staining pattern 
that was linked to selective uptake (Acton et al., 1996). Silver et al. (2001) reported 
that HDL particles are transported to the endosomal recycling compartment. This is in 
contrast to findings that endocytosis is not required for selective cholesteryl ester 
uptake via SR-BI (Nieland et al., 2005).  
2.3.5 Cholesterol metabolism in hepatocytes 
 
Liver cell lines provide a good model for the investigation of the function of SR-BI in 
lipoprotein metabolism for two reasons. First, highest expression mass of SR-BI is 
found in liver (for review see: Krieger, 1999). Second, the liver plays a major role in 
the regulation of the cholesterol homeostasis of the whole body. There exist three 
sources of hepatic cholesterol: endogenous synthesis, receptor-mediated 
endocytosis of LDL and internalization of chylomicron remnants. 
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Once accumulated in hepatocytes, cholesterol has multiple possible fates, according 
to metabolic need. The cholesterol can be incorporated into the cell membranes in 
hepatocytes. Further it is packaged into VLDL particles in its cholesteryl ester form. 
Another possibility is the secretion into the bile, either directly or after metabolization 
to bile acids (Liscum et al., 1980).  
The regulation of hepatic SR-BI expression is regulated by many dietary, metabolic, 
hormonal and pharmalogical factors (Trigatti et al., 2003). 
2.3.6 Cholesterol metabolism in macrophages 
 
As cytosolic accumulation of cholesterol in lipid droplets is involved in atherosclerotic 
lesion development, cholesterol metabolism in macrophages is of great interest. 
The uptake pattern and intracellular processing of cholesterol from LDL and ß-VLDL 
seems to be different (Maxfield et al., 2002). 
It was reported in mouse peritoneal macrophages that human LDL and rabbit ß-
VLDL are both internalized via receptor-mediated endocytosis but the intracellular 
fate differs. LDL is rapidly delivered to lysosomes in the perinuclear area, where it is 
degraded and cholesteryl esters are hydrolyzed. On the opposite side ß-VLDL, which 
was found in vesicles widely distributed throughout the cytoplasm. Additionally, 
compared to LDL, protein degradation and cholesteryl ester hydrolysis were retarded 
(Tabas et al., 1990). 
Internalized LDL is delivered to late endosomes, where cholesteryl ester hydrolysis 
takes place. This source of cholesterol is limited by down-regulation of the LDL-
receptor. This is in contrast to ß-VLDL-derived cholesterol, which becomes 
intracellulary esterified by ACAT resulting in accumulation in cytosolic storage 
droplets. A possible explanation could be the higher cholesterol content of the larger 
ß-VLDL particles (Maxfield et al., 2002). 
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2.4. Scavenger receptor class B, type I (SR-BI) 
2.4.1 Structure and ligands of SR-BI 
 
Scavenger receptor, class B, type I (SR-BI) is a cell surface receptor of 82 kDa 
molecular mass (Fig.3). The receptor consists of two transmembrane domains and 
two cytoplasmic N- and C-
terminal tails. The cysteine-
rich carboxy-terminal is 
important for SR-BI 
signalling. The large 
extracellular region has 
multiple potential N-
glycosylation sites but its 
structure is unknown so far 
(for review see: Rhainds et 
al., 2004).  
 
 
Figure 3: SR-BI protein (Rhainds et al., 2004). 
 
SR-BI was first identified as an HDL-receptor in 1996 (Acton et al.). The class B 
scavenger receptors comprise SR-BI, SR-BII, CD36 and croquemort (Terpstra et al., 
2000). Scavenger receptors typically bind a large spectrum of ligands. Besides HDL 
several other ligands of SR-BI were identified in the last decade. The receptor does 
not only bind native lipoproteins, such as HDL, and LDL, but also modified LDL 
(Calvo et al., 1997), anionic phospholipids (Rigotti et al., 1995), apoptotic cells 
(Murao et al., 1997), advanced glycation end products (Ohgami et al., 2001) and 
even virus particles (Scarselli et al., 2002). SR-BI was also shown to mediate the 
uptake of VLDL and ß-VLDL (Calvo et al., 1997; Herijgers et al., 2000).  
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Higher expression levels of SR-BI are found in liver, where it is involved in RCT, and 
in steroidogenic tissues (adrenal gland, ovary), where it delivers sterol for hormone 
synthesis (Acton et al., 1996). 
2.4.2 The role of SR-BI in the development of atherosclerosis 
 
The anti-atherogenic function of SR-BI is largely ascribed to its contribution in the 
hepatic uptake of cholesteryl esters from HDL. It was shown that disruption of SR-BI 
in wild-type mice led to increased risk for development of atherosclerotic lesions 
(Rigotti et al., 1997). 
SR-BI and apolipoprotein E deficiency was implicated in premature death and severe 
cardiac dysfunction in mice fed a normal chow diet (Braun et al., 2002; Trigatti et al., 
1999). 
Liver-specific overexpression of SR-BI in transgenic mice resulted in a decrease of 
HDL levels and an increase in reverse cholesterol transport (Wang et al., 1998). 
Other studies provided evidence for an anti-atherogenic potential through lowering of 
VLDL and LDL cholesterol levels due to hepatic overexpression of SR-BI (Arai et al., 
1999). 
Those findings together indicate an antiatherogenic function of SR-BI in mice. 
Several other potential mechanisms of atheroprotective effects of SR-BI were 
proposed. SR-BI is expressed in macrophage foam cells in atheroscerotic plaques 
and may therefore influence the flux of cholesterol between HDL and cells. Other 
possible effects of SR-BI include the involvement in α-tocopherol-mediated protection 
mechanisms or a potential impact on arterial oxygen supply (Trigatti et al. 2003).  
Another protein which mediates cholesterol flux to HDL is ABCA1, which is a member 
of a group of transmembrane proteins that use ATP to transport various molecules 
through the plasma membrane. ABCA1 is ubiquitously expressed and transfers lipids 
to apo-AI resulting in the formation of nascent HDL. High expression levels are found 
in macrophages, stimulated by cholesterol loading (Van Eck et al., 2005). 
In contrast to its atheroprotective role, SR-BI facilitated fatty streak development in 
LDL-receptor -/- mice. The property of SR-BI to bind atherogenic lipoproteins, like ß-
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VLDL or oxidized LDL, is suggested to induce foam cell formation, while the efflux of 
intracellular cholesterol to HDL will prevent this event (Fig.4) (for review see: Van Eck 
et al., 2005). Although several studies indicate an atheroprotective function of SR-BI, 
it possibly plays a dual role in macrophages.  
 
Figure 4: The role of macrophage SR-BI in atherosclerotic lesion development 
(Van Eck et al., 2005). 
 
2.4.3 SR-BI localization in caveolae 
 
Another theory that has been examined is the involvement of caveolae in selective 
cholesteryl ester uptake via SR-BI.  
Caveolae were identified as caveolin-containing membrane rafts where SR-BI is 
concentrated. They represent a reversible plasma membrane pool of cholesteryl 
esters (Graf et al., 1999). Matveev et al. (2001) suggested that caveolin-1 is a 
negative regulator of SR-BI mediated selective cholesteryl ester uptake in CHO cells 
overexpressing SR-BI and caveolin-1. However, caveolin-1 overexpression did not 
affect selective lipid uptake from HDL in human embryonic kidney cells and Fischer 
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rat thyroid cells. Transient expression of SR-BI did not alter this result either (Wang et 
al., 2003).  
Further studies analysed the localization of SR-BI in HepG2 cells. The results 
indicate that caveolin-1 does not form caveolae in this liver cell line, as it was 
primarily detected intracellularly. However, SR-BI was found to be concentrated in 
lipid rafts (Rhainds et al., 2004).  
2.5 ß-VLDL  
2.5.1 Characteristics of ß-VLDL 
 
ß-VLDL accumulates in the plasma of patients with type III hyperlipoproteinemia and 
in cholesterol-fed animals (Mahley et al., 1977; Brewer et al., 1983). The 
characteristics of the particle include a density < 1,006 g/ml and ß-electrophoretic 
mobility. The markedly elevated ß-VLDL levels in rabbits fed a high cholesterol diet 
are linked to saturation of hepatic clearance mechanisms. The decreased ß-VLDL 
clearance is also thought to be due to supression of hepatic lipoprotein receptors 
(Kovanen et al., 1981).  
ß-VLDL is relatively enriched in cholesteryl esters compared to normal VLDL. The 
protein part of ß-VLDL consists of multiple apo-E molecules and one apo-B (Fainaru 
et al.,1982), in contrast to VLDL, which mainly consists of apo-B. 
Being the ultimate VLDL remnant, ß-VLDL is widely-used as a model for chylomicron 
remnants and allows investigation of SR-BI in VLDL metabolism independent of 
factors remodelling VLDL particles (such as lipolysis) (Van Eck et al., 2008). 
2.5.2 Atherogenic character of ß-VLDL 
 
The lacking autoregulation of ß-VLDL receptors on macrophages is an important 
aspect concerning atherogenesis. The number of receptors is not sufficiently 
suppressed in response to increasing cellular cholesteryl ester levels, as it is typical 
for the LDL-receptor (Goldstein et al., 1980). ß-VLDL isolated from patients with 
atypical dysbetalipoproteinemia was shown to cause cholesteryl ester accumulation 
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in mouse peritoneal macrophages, thereby converting them into foam cells. The 
lysosomal degradation of internalized ß-VLDL could be inhibited by chloroquine 
indicating a receptor-mediated uptake mechanism (Bersot et al., 1983). 
In mouse peritoneal macrophages, the formation of cholesteryl esters induced by ß-
VLDL was proportional to its amount taken up. Internalized ß-VLDL is hydrolized in 
lysosomes and liberated cholesterol is re-esterified. Other lipoproteins from 
hyperlipidemic dogs slightly increased stimulation of cholesteryl esterification, 
whereas normal VLDL and other lipoproteins did not show an effect on cholesteryl 
ester accumulation (Goldstein et al., 1980). 
2.5.3 SR-BI and ß-VLDL/VLDL uptake: in vitro results 
 
Particles containing apo-E, like VLDL, ß-VLDL or chylomicrons, bind to several 
recognition sites.  
The major apo-E recognizing receptors comprise the LDL-receptor, the LDL-receptor 
related protein (LRP) and the VLDL-receptor, but also heparan sulfate proteoglycans 
(HSPG´s) and SR-BI (Hu et al., 2008).  
The LDL-receptor plays a major role in ß-VLDL metabolism. In order to identify its 
relative importance, several studies were performed using LDL-receptor deficient 
systems (Herijgers et al., 2000; Van Lenten et al., 1985; Perrey et al., 2001). Van 
Lenten et al. (1985) showed that macrophages lacking the LDL-receptor are still able 
to metabolize ß-VLDL.  
Further studies revealed that ß-VLDL induces cholesteryl ester accumulation in the 
absence of the LDL-receptor in macrophages, though to a lesser extent than in LDL-
receptor +/+ macrophages (Herijgers et al., 2000; Van Lenten et al., 1985).  
These results demonstrate the importance of the LDL-receptor in ß-VLDL 
metabolism, but also suggest an alternative recognition site for ß-VLDL on 
macrophages. 
Among several common binding sites for lipoproteins, such as LRP and 
proteoglycans, the data pointed to SR-BI being responsible for ß-VLDL metabolism in 
LDL-receptor -/- macrophages (Herijgers et al., 2000). 
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Furthermore, cell association of ß-VLDL was assessed using hepatocytes from SR-BI 
-/-
 mice. ß-VLDL cell association was reduced in the absence of SR-BI and no 
specific accumulation of degradation products occured (Van Eck et al., 2008). 
2.5.4 SR-BI and ß-VLDL/VLDL uptake: in vivo results 
 
Hu et al. (2008) demonstrated that hepatocytes from LRP -/-, LDL-receptor -/- and 
VLDL-receptor -/- mice are still able to bind VLDL-like emulsion particles. Oxidized 
LDL is an established inhibitor of SR-BI and was therefore used to assess the 
involvement of SR-BI. Heparin releases heparin binding proteins from HSPG´s. The 
cell association of the particle could be inhibited by both oxidized LDL and heparin, 
indicating the involvement of SR-BI and HSPG´s. 
To analyze the role of SR-BI in VLDL metabolism, hepatic uptake and plasma 
clearance of ß-VLDL were assessed in SR-BI knockout and wildtype mice (Van Eck 
et al., 2008). 
Serum VLDL cholesterol levels were elevated in SR-BI -/- mice, on chow diet (4.3% 
fat) as well as on Western-type diet (15% fat, 0.25% cholesterol) and high-cholesterol 
diet (15% fat, 1% cholesterol, 0.5% cholate). This increase was not due to impaired 
lipolysis, decreased hepatic LDL-receptor and LRP-1 expression or increased VLDL 
production. The authors could also observe a delayed serum decay and liver uptake 
of ß-VLDL in SR-BI -/- mice. Interestingly, there was no detectable SR-BI mediated 
selective uptake of cholesteryl esters from ß-VLDL (Van Eck et al., 2008). 
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3. Material and Methods 
3.1 Tissue Culture 
3.1.1 Media 
 
DHG : 1:1 mixture of DMEM and Hams F-12 medium 
MEM: Minimal essential medium (Euro lone) 
DMEM: Dulbecco's minimal essential medium (PAA laboratories GmbH) 
3.1.2 Cell Lines 
HepG2: 
HepG2 are human hepatoma cells that were contained in MEM (minimal essential 
medium) supplemented with 1% penicillin/streptomycin, 10% FCS, 1% non essential 
amino acids and 1% glutamine. HepG2 cells were plated at a density of 300.000 
cells/well in 12-well plates for experiments. 
 
CHO: 
Chinese Hamster Ovarian cells were kept in DHG supplmented with 1% 
penicillin/streptomycin and 5% fetal calf serum (FCS). CHO cells were plated at a 
density of 80.000 cells/well in 12-well plates for experiments. 
 
ldlA7: 
ldlA7 are CHO cells that lack any functional LDL receptor but express normal levels 
of LRP. ldlA7 cells were kept in DHG supplemented with 1% penicillin/streptomycin 
and 5% FCS. 
 
ldlA7-SRBI: 
ldlA7-SRBI are ldlA7 cells that were stably transfected with SRBI. ldlA7-SRBI cells 
were kept in DHG medium supplemented with 1% penicillin/streptomycin, 5% FCS 
and 0.25 mg/ml geneticin (G418).  
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3.2 Buffer 
Phosphate buffered saline (PBS): 
 0.8 % NaCl 
0.02 % KCl  
0.29 % Na2HPO4*12H2O  
0.02 % KH2PO4 
 pH=7.4 
TRIS buffer:    
1.2 % TRIS 
 0.9 % NaCl 
 pH=7.4 
TRIS buffered saline (TBS):  
 0.24 % TRIS 
 0.84 % NaCl 
 pH=7.4 
Sample buffer (4x):    
90 µl Glycerol 
 45 µl TRIS (8 % SDS, pH=6.8) 
 5 % Mercaptoethanol 
 Bromphenol blue 
TRIS-Glycin buffer:    
0.3 % TRIS 
 1.4 % Glycin 
 10% SDS solution (10%) 
Transfer buffer:     
TRIS-Glycin buffer 
 20 % methanol 
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3.3 Bradford protein assay 
 
The protein concentration of lipoproteins as well as of cell lysates was estimated 
using the Bradford protein assay (Bradford MM, 1976).  
This method is based on an absorbance shift of the Coomassie dye when it gets 
bound to protein.   
The assay was performed using microtiter plates. 20µl Bradford reagent (Biorad) and 
2-20µl sample (depending on the expected concentration) were filled up with distilled 
water to a volume of 100µl. Within the same set-up 0, 1, 2, 5 and 10 µg BSA (bovine 
serum albumin) were used for the standard curve. After 10 minutes, the reaction was 
finished. The absorption was measured spectrophotometrically at 595nm using a 
plate reader (Biorad Model 550). The standard curve was used to calculate the 
protein concentration. 
3.4 Isolation of Lipoproteins 
3.4.1 Rabbit ß-VLDL 
 
ß-VLDL was obtained from New Zealand white rabbits that had received a high 
cholesterol diet, containing 2% cholesterol and 10% olive oil for 3 days (Kovanen PT 
et al., 1981). Fasting blood was collected and plasma was obtained by centrifugation 
(3000rpm, 4°C, 30min). The density of ß-VLDL (d=1.006) was adjusted by KBr. 
 
 
 
 
 
The ß-VLDL fraction was isolated by ultracentrifugation according to Mahley et al. 
(1980). 
Ultracentrifuge tubes were filled with the plasma and centrifuged (Beckmann 
ultracentrifuge, rotor=55.2 Ti) at 51000 rpm, at 4°C for 20 hours. The tubes were then 
 
g KBr =    V(plasma) * (final density – initial density) 
1-(0,312 * final density)
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sliced to obtain the ß-VLDL containing plasma at the top of the tubes. The 
ultracentrifugation step was repeated a second time.  
The ß-VLDL containing plasma was transferred into dialysis tubes and kept in 
dialysis buffer (0.9% NaCl, 1% EDTA, pH=7.4) to remove the KBr. After the buffer 
had been changed twice, tubes were maintained within overnight. 
Finally the concentration of ß-VLDL was determined by Bradford protein assay. 
3.4.2 Human VLDL, LDL and HDL 
 
VLDL, LDL and HDL were isolated from human blood. Fasting blood was collected, 
7.2 mM EDTA was added. The further preparation steps were similar to ß-VLDL 
isolation, except for the density adaptation. First, the density of VLDL (d=1.019) was 
adjusted. After an ultracentrifuge step and removement of VLDL containing plasma, 
the density of LDL (d=1.07) was adapted, followed by another cetrifuge step and 
separation of LDL rich plasma. Ultimately, the density of HDL (d=1.22) was adjusted 
and after a last centrifuge step, HDL was obtained. The concentrations of the 
lipoproteins were estimated using the Bradford protein assay. 
3.5 Iodination of lipoproteins 
 
Lipoproteins were labeled with sodium (125) iodide (Hartmann Analytic) using the 
Pierce IODO-BEADS iodination reagent kit. 
In every labeling procedure, the lipoprotein solution (750µg ß-VLDL, 250µg HDL, 
250µg LDL in PBS) was incubated with a iodo-bead and 1 mCi sodium (125) iodide for 
20 minutes at room temperature. Labeled lipoproteins were seperated from free 
sodium (125) iodide by gel chromatography (Pierce D-Salt Dextran Desalting Column). 
First, the storage solution containing 0,02% sodium azide was decanted. The column 
was then equilibrated with 5 column volumes PBS (25ml).  
The lipoprotein solution was applied on the gel after the 20 minutes incubation 
period. The lipoprotein was eluted by five steps with first 750µl and then four times 
500µl PBS. The fractions were collected and the radioactivity (1µl) was measured 
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using a gamma-counter. Finally the protein content was quantified by the Bradford 
protein assay. The ß-VLDL labeling resulted in a specific activity of ~1000 cpm/ng. 
For experiments, labeled ß-VLDL was diluted ~1:5 (~200 cmp/ng) with unlabeled ß-
VLDL. 
3.6 Retroendocytosis experiments 
3.6.1 Association experiments 
 
Cells were seeded on 12-well plates (ldlA7, ldlA7-SRBI, CHO: 80.000 cells/well; 
HepG2: 300.000 cells/well) and grown for 2 days. On day 2 the cells were washed 
twice with sterile PBS and medium was changed overnight to DHG + 5% lpds 
(lipoprotein deficient serum) for ldlA7/ldlA7-SRBI cells and to MEM + 10% lpds for 
HepG2 cells. 
On day 3 the experiment was performed: 
First, medium was removed and cells were washed twice with PBS (37°C). Medium 
[0.5 ml DHG + 2mg/ml faf BSA (fatty acid free bovine serum albumin)] was added. A 
40-fold excess of unlabeled lipoprotein was added to every fourth well to calculate 
unspecific binding. Labeled lipoprotein was added in an amount of 10µg/ml. Aliquots 
from the medium (10µl) were collected to count the specific radioactivity.  
After one hour of incubation at 37°C, the association medium was removed and 
saved for degradation experiments. Cells were washed twice with 50mM TRIS + BSA 
(2 mg/ml) and twice with 50mM TRIS, both ice cold.  
For lysis 0.5 ml 0.1 M NaOH per well were added for 30 minutes at room 
temperature. The radioactivity was counted in aliquots (300 µl) of the cell lysate. The 
amount of protein in the lysates was determined by Bradford protein assay. 
Calculation of specific binding [ng lipoprotein/mg cell protein]: 
 
 
 
(Counts-blank)*(factor/specific activity) 
total protein 
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3.6.2 Displacement experiments 
 
Association experiments were proceeded by a displacement procedure. The 
association media were removed and saved for degradation experiments. Cells were 
washed on ice twice with PBS + BSA (2 mg/ml) and twice with PBS ice cold. Next, 
0.5 ml DHG + BSA (2 mg/ml) and a 50 fold excess of unlabeled lipoprotein per well 
were added. Additionally it was necessary to add HEPES (5µl; 1 M) because of the 
long period out of the incubator. The displacement process took two hours at 0°C. 
Cells were washed twice with 50mM TRIS + BSA (2 mg/ml) and twice with 50mM 
TRIS, both ice cold.  
Cells were lyzed by addition of 0.5 ml 0.1 M NaOH per well for 30 minutes at room 
temperature. The radioactivity was counted in aliquots (300 µl) of the cell lysate. The 
amount of protein in the lysates was determined by Bradford protein assay. 
3.6.3 Chase experiments 
 
Chase experiments started after removal of the displacement media. Cells were 
washed on ice twice with PBS + BSA and twice with ice cold PBS. Then cells were 
incubated for 30 minutes at 37°C with 0.5 ml DHG + BSA (2 mg/ml) and a 20 fold 
excess of unlabeled lipoprotein. Cells were washed twice with 50mM TRIS + BSA (2 
mg/ml) and twice with 50mM TRIS, both ice cold.  
For lysis 0.5 ml 0.1 M NaOH per well were added for 30 minutes at room 
temperature. The radioactivity was counted in aliquots (300 µl) of the cell lysate. The 
amount of protein in the lysates was determined by the Bradford protein assay. 
3.7 Degradation experiments 
 
The media from association experiments were collected, and the protein (400µl) was 
precipitated with 50% trichloroacetic acid. The samples were kept at least 1 hour at 
4°C. Next, the TCA soluble degradation products were seperated from the pellet. 
After centrifugation (4°C, 10 min, 4000 rpm) 400µl of the supernatant were 
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transferred into glass tubes. In order to remove free iodide, 40% potassium iodide 
(10µl) and 30% hydrogen peroxide (40µl) were added. Samples were mixed and after 
5 minutes chloroform (1 ml) was added to extract the supernatant. Samples were 
again mixed and after ~10 minutes, 150µl of the upper aqueous phase were counted 
to assess the degradation activiy. The amount of acid-soluble products (mainly [125I] 
iodotyrosine) is expressed in ng/mg cell protein. 
3.8 Oil Red O Staining 
 
The Oil Red O solution was prepared according to Ramirez-Zacarias JL et al. (1992). 
Cells were grown in 12-well plates and cholesterol depleted overnight. On day 3 they 
were incubated with 0, 5 or 10 µg/ml ß-VLDL overnight. Lipoproteins were therefore 
sterile filtrated. On day 4, cells were washed twice with PBS and then incubated with 
500µl/well Oil Red O solution at room temperature. After 2 hours, cells were washed 
twice with PBS and the dye was extracted by adding 1 ml/well isopropanol for 10 
minutes. The absorption was estimated photometrically in the supernatant at 510nm 
against isopropanol as blank value. The cells were lyzed with 1ml/well 0,1 M NaOH 
for 1 hour at room temperature. The protein concentration was measured using the 
Bradford protein assay.  
The values were normalized to total cell protein. 
3.9 Western Blot analysis 
3.9.1 Preparation of cell lysates 
 
Cells were grown in 6-well plates and washed twice with PBS on ice. Lysis buffer 
(62.5 mM Tris, 8 M Urea, 20 mM EDTA, 20 mM EGTA, 10 % Glycerol, 1 % SDS, pH 
6.8) (50µl/well) was added, containing 1% protease inhibitor (Sigma). After 10 
minutes of incubation on ice, the cell lysates were transferred into tubes and 
homogenized by 3 seconds ultrasonic treatment followed by 1 minute in liquid 
nitrogen. The cell lysates were then centrifuged by 12000 rpm for 10 minutes at 4°C. 
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The supernatants were collected and the protein content was quantified 
photometrically at 280nm. The lysates were stored at -20°C. 
 
For the Western blot analysis the concentrations of the cell lysates were adjusted 
with PBS. The lysates were mixed with sample buffer in a ratio of 1:4. This sample 
mixture was heated for 30 minutes at 40°C.  
3.9.2 Preparation of the gel 
 
Glass plates were assembled for a gel of 0.75 mm thickness. The gels were 
prepared according to the table. The resolving gel was poured and sealed with 
isopropanol.  
When the resolving gel had set, the stacking gel was poured and the comb (10 or 15 
slots according to sample number) was inserted.  
 
 Resolving Gel (8%) Stacking Gel (4%) 
Distilled water 1.6 ml 1.1 ml 
3 M TRIS (pH 8.45; 0.3% SDS) 1.1 ml 0.3 ml 
30% Acrylamid 1.3 ml 0.7 ml 
10% APS 30 µl 20 µl 
TEMED 3 µl 2 µl 
 
3.9.3 Running the gel 
 
The electrophoresis chamber was filled with running buffer (Tris Glycin) and the gel 
was inserted. The slots were flushed with buffer and loaded with the samples (10 
slots: 20µl; 15 slots: 12µl). 
A prestained protein standard (Fermentas) was also applied (~2 µl) to one lane. 
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The electrophoresis was run with constant voltage of 180 V with a current of ~60 mA 
per gel for 80 minutes. 
3.9.4 Membrane transfer 
 
The sandwich was assembled as follows: sponge – filter paper – nitrocellulose 
membrane (Amersham, Hybond-C) – gel – filter paper – sponge. The filter papers, 
sponges and the membrane were prewetted in tranfer buffer. The sandwich was 
inserted in the electrophoresis chamber that was filled with transfer buffer. The 
electrophoresis was run with constant current of 400 mA and voltage >100 V for 45 
minutes.  
 
The membrane was stained with Ponceau Red (0.1 g Ponceau S were dissolved in 5 
ml acetic acid and filled up to 100 ml with distilled water) to visualize the protein 
bands. The membrane was then washed several times with a washing buffer (TBS, 
0.1 % Tween). In order to reduce unspecific binding the membrane was incubated 
with blocking buffer (TBS, 5 % milk powder) for 1 hour. Thereafter the membrane 
was washed three times for 10 minutes with washing buffer.  
The specific antibody (SR-BI/BII rabbit antibody, Novus biologicals) was added to a 
solution of washing buffer (3 % BSA, sodium azid) at a dilution of 1:1000. Beta-Actin 
(beta-Actin mouse antibody, Biorad) was used as a loading control. The membrane 
was incubated with the antibodies overnight at 4°C. 
On day 2 the membrane was again washed by three steps. 
The second antibody (rabbit anti-goat, Pierce; mouse anti-goat, Sigma) was added at 
a dilution of 1:10000 to the buffer solution (TBS, 5 % milk powder). After one hour of 
incubation the membrane was washed three times. 
Finally, the membrane was incubated for 10 minutes with a chemiluminescent 
substrate (Super Signal, Pierce) and then analyzed in a chemiluminescent imager. 
3.10 Inhibitors of intracellular cholesterol transport 
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Several inhibitors blocking intracellular cholesterol transport were used to analyze 
their effect on ß-VLDL derived cholesterol. 
3.10.1 Chloroquine  
 
Chloroquine is a weak base and raises the intracellular pH. This impairs several 
pathways that require a low pH, such as the intracellular cholesterol transport. It 
blocks the cholesterol transport from lysosomes to the endoplasmic reticulum by 
inhibiting the lysosomal acidic hydrolase (De Duve et al., 1974). LDL accumulates in 
lysosomes as a consequence of this process. 
3.10.2 U18666A 
 
U18666A inhibits the cholesterol transport from both the plasma membrane and the 
lysosomes to the endoplasmic reticulum (Liscum et al., 1992).  
3.10.3 Imipramine 
 
Imipramine is a hydrophobic amine as well as U18666A. It blocks the transport of 
cholesterol out of the lysosome (Liscum et al., 1992).  
3.10.4 Monensin 
 
Monensin is a monovalent carboxylic ionophore that interferes with vesicular 
transport. It disrupts LDL endocytosis through coated pits (Basu et al., 1981) and the 
transit of membrane vesicles from the Golgi apparatus to the plasma membrane 
(Tartakoff et al., 1983). The recycling of the LDL receptor to the plasma membrane is 
impaired.  
 
Association experiments were performed to analyse the effect of the mentioned 
inhibitors on ß-VLDL cell association. Therefore cells were preincubated for 15 
minutes with 50 µM chloroquine, monensin, imipramine or U18666A. 
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3.11 SR-BI knockdown in HepG2 cells 
 
The SR-BI knockdown was performed using a lipid-based agent for reverse 
transfection (siPORTTM NeoFXTM Transfection Agent, Applied Biosystems).  
A HepG2 cell suspension was prepared containing ~106 cells in 2.3 ml MEM 
medium. Next, 5 µl siPORT were diluted into 100 µl OPTI-MEM I medium (Invitrogen) 
and incubated at room temperature for 10 minutes. After that 5 µl siRNA (5 µmol/L) 
were also diluted into 100 µl OPTI-MEM I medium. The two solutions were then 
combined and incubated for 10 minutes at room temperature. The mixture was 
dispensed into cell culture plates (6-well plates) and overlayed with the prepared cell 
suspension. The transfected cells were then incubated under normal cell culture 
conditions. The medium was exchanged the next day. On day 2, medium was 
changed to MEM with 10 % lpds. After overnight cholesterol depletion an association 
experiment was performed.   
3.12 High performance liquid chromatography (HPLC) 
 
Cells were grown in 6 cm dishes for 1 day at a density of 80.000 cells/dish (ldlA7, 
ldlA7-SRBI) and 300.000 cells/dish (HepG2). On day 2, they were depleted of 
cholesterol overnight. On day 3, ldlA7 and ldlA7-SRBI cells were incubated with 0, 5 
or 10 µg/ml sterile filtrated ß-VLDL overnight, HepG2 cells were incubated for 6 
hours. After the incubation period, cells were washed twice with PBS+BSA (2 mg/ml) 
and afterwards twice with PBS. Cells were then incubated with 3 ml 
hexane:isopropanol (3:2) for 30 minutes to extract the lipids. In order to quantify the 
intracellular cholesterol, an internal standard of ergosterol (12 µg/dish, dissolved in 
hexane:isopropanol) was added. The extracted solution was transferred into glass 
tubes and cells were washed with another 3 ml hexane:isopropanol, which was also 
transferred into the glass tubes.  
After extraction of the lipid content, cells were lyzed with 0.1 M NaOH and the protein 
was quantified using the Bradford protein assay. 
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The collected extract (6 ml) was separated into two aliquots. For analysis of free 
cholesterol (FC), one aliquot was dried under N2 and taken up in 1 ml 
ethanol:chloroform (8:2). For analysis of total cholesterol (TC), the cholesteryl esters 
(CE) were saponified at 70 °C for one hour using 5 ml ethanolic KOH (3 %). The 
samples were mixed every ten minutes during the saponification. After the tubes had 
reached room temperature, 5 ml distilled water were added and the lipids were 
extracted with 10 ml hexane:isopropanol. The upper organic phase was collected 
after vortexing for 30 seconds. The lower phase was extracted a second time with 10 
ml hexane:isopropanol. The upper phase was again removed and combined with the 
first extract. The solution was dried under N2 and taken up in 1 ml ethanol:chloroform.  
Both aliquots were filtrated through a syringe filter (sterile Acrodisc, 0.45 µm, Gelman 
Sciences) into HPLC screw neck vials and applied to HPLC analysis. 
HPLC analysis was performed on a separation module (Waters 2695, Waters) using 
a Nova-Pack C184 µm column (3.9 x 150 mm) and a dual absorbance detector 
(Waters 2487, Waters) at a wavelenght of 210 nm. Acetonitril:isopropanol (80:20) 
was used as running solution at a constant flow of 1 ml/minute. Every sample was 
run for 30 minutes. 
 
Figure 5: Representative HPLC-peaks of ergosterol and cholesterol.  
 
Ergosterol was detected after ~5.6 minutes, cholesterol after ~7.6 minutes. 
The areas under both peaks were measured for quantification. The cholesterol peak 
area was related to the ergosterol peak area and to the protein content for calculation 
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of the total cholesterol content and the free cholesterol content respectively. The 
cholesteryl ester content was calculated as total cholesterol content minus free 
cholesterol content.  
The HPLC column was flushed with distilled water for 1 hour to remove excess 
acetonitril and with 50% methanol for several hours at a column temperature of 50°C 
to remove the residual lipids from the column. 
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4. Results and Discussion
 
 
The aim of the study was to assess the function of SR-BI in ß-VLDL metabolism. 
Several lines of evidence indicate a major role of the LDL-receptor in ß-VLDL uptake 
(Herijgers et al., 2000; Van Lenten et al., 1985; Perrey et al., 2001). Therefore, ß-
VLDL metabolism was analyzed in two different sets of cells. First, we used Chinese 
Hamster Ovarian cells (CHO) and as a more physiological model, the human liver 
cell line HepG2, which both express normal levels of the LDL-receptor and LRP. 
Second, we analyzed CHO cells that lack the LDL-receptor termed ldlA7 as well as 
SR-BI overexpressing ldlA7-SRBI cells. 
4.1 Cell association and competition experiments 
4.1.1 ß-VLDL cell association in ldlA7 and ldlA7-SRBI cells 
 
Recent studies demonstrated reduced ß-VLDL cell association in hepatocytes from 
SR-BI knockout mice compared to wildtype mice. Furthermore in vivo results suggest 
an impact of SR-BI in ß-VLDL metabolism (Van Eck et al., 2007). 
SR-BI overexpressing cells were used to evaluate the role of SR-BI in ß-VLDL 
metabolism. 
ß-VLDL cell association was measured after 1 hour of incubation with increasing 
concentrations of [125I]-ß-VLDL in ldlA7 and ldlA7-SRBI cells (Fig. 6). The aim of this 
experiment was to assess whether SR-BI overexpression increases ß-VLDL cell 
association. 
Both cell lines showed a dose dependent increase in ß-VLDL cell association. As 
expected, the dose response in SR-BI overexpressing cells was much higher. 
Incubation with 20 µg/ml iodinated ß-VLDL resulted in a cell association of 254 ± 7 ng 
ß-VLDL/mg cell protein in ldlA7-SRBI cells compared to 105 ± 4 ng ß-VLDL/mg cell 
protein in ldlA7 cells. These results confirm the contribution of SR-BI in ß-VLDL cell 
association, which was more than doubled due to SR-BI overexpression. The fact 
that ldlA7 cells still show a considerable amount of ß-VLDL association raises the 
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question whether other receptors might contribute to ß-VLDL binding. One possible 
binding site could be LRP, as ldlA7 cells express normal levels of this receptor. 
Besides the LDL-receptor family, several other uptake mechanisms have been 
discussed for VLDL and chylomicrons. Ioka et al. (2003) identified the 22kDa protein 
glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 
(GPIHBP1). It was first described to mediate the binding of HDL (Ioka et al., 2003). 
Further studies (Beigneux et al., 2007) analyzed its role in the lipolytic processing of 
chylomicrons. GPIHBP1 -/- mice exhibited chylomicronemia on normal chow diet and 
GPIHBP1 was shown to bind chylomicrons as well as LPL, suggesting an important 
role in the metabolism of triglyceride-rich particles. These findings make GPIHBP1 an 
alternative candidate for ß-VLDL uptake, though it could not be detected in tissue 
culture cells (Beigneux et al., 2007). 
Another receptor that was shown to mediate chylomicron remnant uptake is ß-chain 
ATPase (Beisiegel et al., 1988). It might therefore play a role in ß-VLDL metabolism. 
 
Figure 6: [125I]-ß-VLDL cell association in ldlA7 and ldlA7-SRBI cells. 
ldlA7 and ldlA7-SRBI cells were seeded into 12-well plates at a density of 
80000 cells/well. Cells were grown for 2 days followed by cholesterol depletion 
overnight with DHG supplemented with 1% Penicillin/Streptomycin and 5% lpds. 
On day 3, cells were washed twice with PBS and fed with DHG containing 1% 
Penicillin/Streptomycin and 2 mg/ml faf BSA. After incubation with increasing 
concentrations of [125I]-ß-VLDL for 1 hour, cells were washed and lyzed as 
described in the methods section. Aliquots from the cell lysates were counted 
and specific cell association was calculated. 
 
0 20 40 60 80
0
200
400
600 ldlA7-SRBI
ldlA7
ß-VLDL (µg/ml)
ß-
V
LD
L
(n
g/
m
g 
ce
ll 
pr
o
te
in
)
  33 
The data represent mean ± SD of two independent experiments. 
The results are expressed in ng ß-VLDL/mg cell protein. 
ß-VLDL 
(µg/ml) 
2 4 10 20 40 60 80 
ldlA7-SRBI 45 ± 8 88 ± 23 150 ± 13 254 ± 7 423 ± 110 495 ± 26 531 ± 106 
ldlA7 9 ± 1 20 ± 4 68 ± 3 105 ± 4 131 ± 23 188 ± 25 260 ± 119 
 
4.1.2 Association of [125I]-ß-VLDL competed by HDL, LDL and ß-VLDL 
 
For a more detailed characterization of ß-VLDL binding, competition experiments 
were performed. 
Van Eck et al. (2007) performed competition experiments with a similar set-up in 
hepatocytes from SR-BI +/+ and SR-BI -/- mice. They could show a decrease in ß-
VLDL cell association after addition of a 10-fold excess of ß-VLDL (by ~80-90 %) , 
HDL (by ~55 %) and LDL (by ~30 %) in both cell types. Interestingly, HDL competed 
effectively for ß-VLDL binding also in the absence of SR-BI. 
Competition experiments were performed by coincubating 10µg/ml [125I]-ß-VLDL with 
a 10-fold excess of either ß-VLDL, HDL or LDL (Fig. 7). 
Cell association of ß-VLDL was about 2-fold higher in SR-BI overexpressing cells 
compared to the parental cell line ldlA7. In CHO cells, which exhibit a functional LDL 
receptor, cell association was about 5-fold higher. 
There was a considerable reduction of ß-VLDL association in ldlA7 and ldlA7-SRBI 
cells due to addition of a 10-fold excess of unlabeled ß-VLDL, indicating specific 
binding. The effect of a 10-fold excess of unlabeled HDL or LDL was much lower. 
CHO and HepG2 cells showed a similar competition pattern. ß-VLDL association was 
well competed with LDL and ß-VLDL, but not with HDL. These differences can be 
ascribed to the contribution of the LDL receptor in CHO and HepG2 cells. 
The competition pattern demonstrates that ß-VLDL is taken up differently by the 
cells. In HepG2 and CHO cells the particle is mainly internalized by the LDL-receptor, 
whereas in ldlA7 and ldlA7-SRBI cells it is preferentially taken up via SR-BI. 
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ß-VLDL cell association was about 2-fold higher in CHO cells compared to SR-BI 
overexpressing cells, indicating that the LDL receptor plays an important role in ß-
VLDL metabolism. These findings are in line with several studies that have 
elucidated the major role of the LDL-receptor in ß-VLDL metabolism (Herijgers et al., 
2000; Van Lenten et al., 1985). The SR-BI pathway might be of particular importance 
in cases, where the LDL receptor pathway is defective. 
 
Figure 7: Association of [125I]-ß-VLDL competed by HDL, LDL and ß-VLDL. 
Cells were grown and treated as described in Figure 6. In order to investigate 
the influence of lipoproteins on ß-VLDL cell association, a 10-fold excess of 
unlabeled lipoproteins (HDL, LDL or ß-VLDL) was added. Aliquots of the cell 
lysates were counted and specific cell association was calculated. 
0
50
100
150 ldlA7-SRBI
n
g 
ß-
V
L
D
L
/m
g 
ce
ll 
pr
o
te
in
 
0
50
100
150 ldlA7
    
0
50
100
150
HepG2
n
g 
ß-
V
LD
L/
m
g 
ce
ll 
pr
o
te
in
 
0
50
100
150
200
250
300
350 ß-VLDL
+ 10x HDL
+ 10x LDL
+ 10x ß-VLDL
CHO
 
The data represent mean ± SD of three independent experiments (ldlA7-SRBI: 
n=4). ß-VLDL cell association is expressed in ng ß-VLDL/mg cell protein. 
 ß-VLDL (control) + 10x HDL + 10x LDL + 10x ß-VLDL 
ldlA7-SRBI 115 ± 39 63 ± 24 99 ± 35   3 ± 12 
ldlA7 61 ± 11 52 ± 17 46 ± 15 13 ± 10 
HepG2 73 ± 23 68 ± 28 19 ± 12 35 ± 13 
CHO 278 ± 28 254 ± 101 112 ± 62 153 ± 78 
  35 
4.1.3 Association of [125I]-HDL or [125I]-LDL competed by ß-VLDL 
 
Cells lacking the LDL-receptor (ldlA7-SRBI) and HepG2 cells were compared with 
regard to inhibitory effects of ß-VLDL on HDL and LDL cell association (Fig. 8). 
In ldlA7-SRBI cells no effect of ß-VLDL on HDL cell association was observed, but 
LDL cell association was reduced by ~80 %. An explanation for the lacking inhibition 
of HDL association could be the abundance of SR-BI or different binding sites. A 
different pattern was observed in HepG2 cells. Both HDL as well as LDL association 
was well competed by ß-VLDL. HDL and LDL cell association were both reduced by 
~80 %. HepG2 cells contain few SR-BI compared to ldlA7-SRBI cells which could be 
the reason for the competitive effect of ß-VLDL on HDL cell association. ß-VLDL 
preferentially binds to members of the LDL-receptor family, present in HepG2 cells, 
and thereby impaires LDL cell association. 
 
Figure 8: Association of [125I]-HDL or [125I]-LDL competed by ß-VLDL. 
Cells were grown and treated as described in Figure 6. HepG2 cells were plated 
at a density of 300000 cells/well. On day 3, cells were washed twice with PBS 
and fed with DHG containing 1% Penicillin/Streptomycin and 2 mg/ml faf BSA. 
Iodinated Lipoprotein (HDL or LDL) was added right after a 10-fold excess of 
unlabeled ß-VLDL in a concentration of 10 µg/ml. Control cells were incubated 
without the addition of ß-VLDL. After one hour of incubation, aliquots from the 
cell lysates were counted and specific cell association was calculated.  
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The data represent mean ± SD of three independent experiments. 
HDL and LDL cell association competed by ß-VLDL is expressed in % of 
control. 
 HDL + 10x ß-VLDL LDL + 10x ß-VLDL 
HepG2 18.0 ± 9.7 19.5 ± 14.3 
LdlA7-SRBI 96.4 ± 26.8 18.1 ± 14.3 
 
 
4.2. [125I]-ß-VLDL binding, uptake and resecretion 
 
Next we assessed, whether associated ß-VLDL was metabolized by the cells. 
Therefore, we performed association experiments followed by extensive washing and 
incubation with a 50-fold excess of unlabeled ß-VLDL for 2 hours at 0°C 
(displacement). Displacement experiments were performed to analyze whether 
associated ß-VLDL was taken up by the cells. There was no alteration in the amount 
of radioactivity between the association and the displacement lysates observed (Fig. 
9). This data indicates an holoparticle uptake of almost all of the associated ß-VLDL. 
Since it was previously shown (Pagler et al., 2007) that HDL internalized by SR-BI 
can be resecreted (“retroendocytosis”), we performed the same experiment with ß-
VLDL. For resecretion experiments (chase), cells were extensively washed after the 
displacement and further incubated with a 20-fold excess of unlabeled ß-VLDL for 30 
minutes at 37°C to analyze the resecretion of the particle. The radioactivity did not 
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even change in the chase lysate meaning that the particle could not be released back 
to the media.  
Again, cell association in ldlA7-SRBI cells was about 2-fold higher than in ldlA7 cells 
(compare Fig. 7). 
In summary, it can be said that the vast majority of associated ß-VLDL is taken up by 
the cells and can not be released back to the media. 
 
Figure 9: [125I]-ß-VLDL binding, uptake and resecretion. 
Cells were grown and treated as described. After one hour of association with 
10µg/ml [125I]-ß-VLDL, cells were washed and bound [125I]-ß-VLDL was 
displaced for 2 hours at 4°C using a 50-fold excess of unlabeled lipoprotein. To 
analyse if the particle is released back to the media, internalized [125I]-ß-VLDL 
was chased for one hour with a 20-fold excess of unlabeled lipoprotein at 37°C. 
The radioactivity of the cell lysats was counted. 
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The data represent mean ± SD. 
The results are expressed in ng ß-VLDL/mg cell protein. 
 Association (n=5) Displacement (n=4) Chase (n=2) 
ldlA7-SRBI 115 ± 39 113 ± 27  120 ± 21 
ldlA7 58 ± 11  34 ± 21 43 ± 11 
 
4.3. Time course of [125I]-ß-VLDL association and degradation. 
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In order to investigate the fate of internalized ß-VLDL, we performed a time course 
experiment measuring association and degradation at several time points. 
ß-VLDL cell association and degradation were measured in ldlA7 and ldlA7-SRBI 
cells over a 24 hour period (Fig. 10).  
There was a time dependent decrease of ß-VLDL association and a corresponding 
increase of degradation in both cell lines. ß-VLDL was degraded at a rate of 6 ng per 
hour. The catabolism of the particle is slow, possibly due to the particle size. 
Similar results were found in HepG2 cells. The time dependent decrease of 
radioactivity in the cell lysate was accompanied by an increase in TCA-resistant 
radioactivity in the media. 
After 24 hours about 2/3 of the ß-VLDL was degraded. This indicates that ß-VLDL is 
metabolized faster in HepG2 cells, where the LDL receptor is present. 
 Previous studies reported that there was no specific accumulation of degradation 
products detectable in hepatocytes isolated from SR-BI +/+ or SR-BI -/- mice (Van Eck 
et al., 2007). Tabas et al. (1990) found reduced ß-VLDL degradation in peritoneal 
macrophages compared to LDL, which was degraded more rapidly. 
The degradation of ß-VLDL appeared to be very slow, however we could clearly 
detect degradation products which is in line with the findings of Tabas et al. (1990). 
 
Figure 10: Time course of [125I]-ß-VLDL association and degradation. 
Cells were seeded on 6 cm dishes for 2 days. Cells were depleted of 
cholesterol overnight. On the experimental day, cells were washed twice with 
PBS and fed with DHG containing 1% Penicillin/Streptomycin, 2 mg/ml faf BSA 
and 10 µg/ml iodinated ß-VLDL. After one hour media were removed and cells 
were washed twice with PBS. Next DHG with 2 mg/ml faf BSA was added. 
From there on cells were washed and lyzed at several time points up to 24 
hours. Media were removed to perform degradation experiments.  
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The data represent mean ± SD of two independent experiments. 
The results are expressed in ng ß-VLDL/mg cell protein. 
 
 
 
 
 
 
 
 
 
 
Association 
Hours ldlA7-SRBI ldlA7 HepG2 
0 208 ± 105  148 ± 5 173 ± 4 
1 195 ± 23 71 ± 27 106 ± 1 
2 158 ± 48 40 ±1 82 ± 7 
3 148 ± 6 41 ± 28 77 ± 1 
6 122 ± 30 45 ± 4 48 ± 3 
9 114 ± 1 41 48 ± 4 
12 99 ± 21 40 39 ± 14 
24 69 ± 2 26 29 ± 1 
Degradation 
ldlA7-SRBI ldlA7 HepG2 
0 ± 0 0 ± 0 0 ± 0 
19 ± 2 23 ± 2 31 ± 20 
28 ± 2 23 ± 5 28 ± 2 
35 ± 5 24 ± 2 22 ± 4 
32 ± 4 21 ± 2 25 ± 4 
42 ± 5 20 23 ± 4 
52 ± 2  45 33 ± 11 
97 ± 13 30 36 ± 4 
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4.4. Effect of inhibitors of intracellular cholesterol transport on [125I]-ß-
VLDL cell association 
 
To gain more knowledge of the mechanisms underlying ß-VLDL uptake, the effect of 
inhibitors blocking intracellular cholesterol transport on ß-VLDL uptake was assessed 
in HepG2 and ldlA7-SRBI cells (Fig. 11). In order to analyse the cholesterol transport 
between cellular compartments, inhibitors of different stages of intracellular 
cholesterol transport are useful instruments, for example hydrophobic amines, such 
as imipramine or U18666A, that block cholesterol transport out of the lysosomes 
(Liscum et al., 1992).  
Chloroquine, which is a pH-raising agent, inhibits the lysosomal hydrolases (De Duve 
et al., 1974). 
In both cell lines, preincubation with 50µM chloroquine, imipramine, monensin or 
U18666A did not substantially alter ß-VLDL cell association.  
The experiment was repeated several times, but did not provide proper results due to 
decreased total cell protein levels. However, the radioactivity measurements in the 
cell lysates also indicated almost no alteration of the cell association compared to the 
control. This either suggests that there is no influence of the inhibitors on the 
trafficking of ß-VLDL derived cholesterol or that alternative endocytic pathways are 
activated. 
Treatment of HepG2 cells with chloroquine blocked the hydrolysis of LDL- (by 89 %) 
and HDL-cholesteryl esters (by 52 %) but did not impair the uptake of cholesteryl 
esters. This inhibitory effects indicate that LDL is mostly degraded in lysosomes, 
whereas HDL is partially hydrolyzed in an extralysosomal compartment (Rhainds et 
al., 1999).  
Previously, several inhibitors were used to assess their effect on HDL 
retroendocytosis in SR-BI overexpressing ldlA7 cells. Retroendocytosis of HDL 
involves the holo-particle uptake and resecretion of HDL, in contrast to LDL uptake. 
Chloroquine, imipramine, monensin or U18666A treatment did not significantly alter 
HDL uptake and resecretion (Pagler et al., 2007) in ldlA7-SRBI cells. 
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Figure 11: Effects of inhibitors on [125I]-ß-VLDL cell association. 
Cells were grown and treated as described. 
HepG2 and ldlA7-SRBI cells were preincubated for 15 minutes with 50µM 
chloroquine, imipramine, monensin or U18666A. Afterwards an association 
experiment was performed. 
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The data represent mean ± SD of one representative experiment out of five. 
The results are expressed in ng ß-VLDL/mg cell protein. 
 Control Chloroquine Imipramine Monensin U18666A 
ldlA7-SRBI 130 ± 17 119 ± 24 104 ± 14 122 ± 10 126 ± 27 
HepG2 30 ± 7 46 ± 5 35.67 ± 12 25 ± 4 35 ± 6 
 
4.5. SR-BI knockdown did not impair [125I]-ß-VLDL cell association 
 
Former studies analyzed the association and degradation of ß-VLDL particles in 
hepatocytes isolated from SR-BI knockout mice. As a consequence of SR-BI 
absence, ß-VLDL cell association was reduced and no specific accumulation of 
degradation products was detected (Van Eck et al., 2007). 
SR-BI knockdown is another tool to assess the importance of the receptor in ß-VLDL 
metabolism.  
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Western blot analysis of SR-BI knockdown in HepG2 cells revealed a decreased 
expression of SR-BI of ~50% compared to control cells (Fig. 12).  
ß-VLDL cell association was assessed comparing HepG2 control and SR-BI 
knockdown cells (Fig. 13). The same experiment was performed with HDL cell 
association (data not shown). Neither ß-VLDL nor HDL cell association was altered in 
siRNA treated cells. This all together indicates that other pathways might 
compensate for diminished SR-BI function. These results agree with the data from 
the competition experiments (compare Fig. 7). 
However, hepatocytes from SR-BI knockout mice showed decreased ß-VLDL cell 
association (1.6 fold lower) compared to SR-BI +/+ hepatocytes (Van Eck et al., 2007). 
 
Figure 12: Western blot analysis of SR-BI knockdown cells. 
HepG2 SR-BI knockdown and control cells were lyzed and analysed by western 
blot. 98 µg sample per lane were applied in dublicates. SR-BI was detected 
using a SRBI/BII antibody. ß-actin was used as a loading control. 
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Figure 13: SR-BI knockdown did not impair [125I]-ß-VLDL cell association. 
SR-BI was knocked down in HepG2 cells using siRNA as described in the 
methods section. On day 2, medium was changed to MEM with 10 % lpds. After 
overnight cholesterol depletion an association experiment was performed.  
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The data represent mean ± SD of three independent experiments. 
The results are expressed in % of control. 
 SR-BI knockdown 
HepG2 95.32 ± 11.19 
  
4.6. ß-VLDL feeding increased the cellular lipid pool 
 
We further questioned whether ß-VLDL derived lipid increases the cellular lipid 
content. We assessed alterations in the lipid pool of HepG2, ldlA7 and SR-BI 
overexpressing cells after ß-VLDL feeding, using two different methods. First, we 
used the Oil Red O method, which allowed a semi-quantitative determination of the 
cellular lipid content (triglycerides and cholesteryl esters) (Fig. 14). Second, we 
analyzed the cellular cholesterol content using HPLC (Fig. 15, Fig. 16).  
The lipid content increased dose-dependently in both cell lines, ldlA7 and ldlA7-SRBI, 
after overnight ß-VLDL feeding. Incubation with 10 µg/ml ß-VLDL led to an increase 
of ~100% compared to control. The dose response was again higher in SR-BI 
overexpressing cells (Fig. 14, compare Fig. 6). 
The total cholesterol content (TC) increased in both cell lines (ldlA7, ldlA7-SRBI) after 
incubation with increasing concentrations of ß-VLDL overnight. Both, a rise in free 
cholesterol as well as in the cholesteryl ester content contributed to this increase. 
The TC more than doubled in both cell lines after incubation with 10 µg/ml ß-VLDL 
compared to control (Fig. 15). These data are in line with the results from the Oil Red 
O test and indicate an utilization of ß-VLDL derived cholesterol by the cells. The 
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increase in the CE content points to the storage of excess cholesterol as cholesteryl 
esters. 
The increase of the lipid content in HepG2 cells after ß-VLDL feeding was mainly due 
to an increase in TC and CE. The FC content just increased slightly (Fig. 17). Similar 
results were obtained from the Oil Red O test. There was just a little increase in the 
cellular lipid content even after incubation with 10 µg/ml ß-VLDL (Fig. 16). However, 
cholesterol delivered via ß-VLDL particles reaches the intracellular lipid pool in 
HepG2 cells.  
Taken together, these results show that ß-VLDL derived lipid is utilized by all three 
cell lines. 
 
Figure 14: ß-VLDL feeding increased cellular lipid pool in ldlA7 and ldlA7-
SRBI cells. 
ldlA7 and ldlA7-SRBI cells were seeded on 12-well plates. On day 1, cells were 
cholesterol depleted overnight. On day 3, cells were incubated with 500µl Oil 
Red O solution after overnight (18 h) incubation with 0, 5 or 10 µg/ml ß-VLDL. 
The extinction of the extracted dye was measured at 510 nm and normalized to 
total cell protein. 
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The data represent mean ± SD of three independent experiments. 
The results are expressed in extinction (510nm)/mg cell protein. 
  45 
 
  
 
 
Figure 15: Analysis of the cellular cholesterol content in ldlA7 and ldlA7-
SRBI cells. 
ldlA7 and ldlA7 cells were plated in 6 cm dishes at a density of 80.000 
cells/dish. After overnight cholesterol depletion, they were incubated on day 2 
with 0, 5 or 10 µg/ml ß-VLDL overnight. Free cholesterol (FC) and total 
cholesterol (TC) content were measured by HPLC. The cholesteryl ester (CE) 
content was calculated as total cholesterol minus free cholesterol.  
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The data represent mean ± SD of triplicate values of one representative 
experiment out of three. 
Results are expressed in µg cholesterol(respectively cholesteryl esters)/mg 
cell protein. 
 
ldlA7-SRBI  0 µg/ml ß-VLDL 5 µg/ml ß-VLDL 10 µg/ml ß-VLDL 
FC  3.5 ± 0.6 8.8 ± 2.8 8.7 ± 1.1 
CE 2.6 ± 1.2 8.3 ± 3.2 8.3 ± 1.2 
TC 6.1 ± 0.6 17.1 ± 0.3 17.0 ± 0.2 
ldlA7    
FC 5.0 ± 2.8 9.5 ± 0.1 10.4 ± 0.2 
CE 1.7 ± 2.7 4.6 ± 1.7 5.3 ± 3.4 
TC 6.7 ± 0.1 14.2 ± 1.5 15.7 ± 3.6 
µg ß-VLDL 0 5 10 
ldlA7-SRBI 1.42 ± 0.6 2.47 ± 0.7 3.16 ± 0.8 
ldlA7 1.11 ± 0.5 1.83 ± 0.9 2.10 ± 0.9 
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Figure 16: ß-VLDL feeding increased cellular lipid pool in HepG2 cells. 
Cells were treated as described in Fig. 14. 
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 The data represent mean ± SD of three independent experiments. 
 Results are expressed in E (510nm)/mg cell protein. 
 
µg/ml ß-VLDL 0 5 10 
HepG2 2.25 ± 0.6 3.48 ± 1.1 2.72 ± 1.0 
 
 
Figure 17: Analysis of the cellular cholesterol content in HepG2 cells. 
 
HepG2 cells were plated in 6 cm dishes at a density of 300.000 cells/dish. 
After overnight cholesterol depletion, they were incubated with 0, 5 or 10 µg/ml 
ß-VLDL for 6 hours. FC and TC content were measured by HPLC. The CE 
content was calculated as TC minus FC.  
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The data represent mean + SD of triplicate values of one representative 
experiment out of three. The results are expressed in µg cholesterol 
(respectively CE)/mg cell protein. 
 
HepG2 0 µg/ml ß-VLDL 5 µg/ml ß-VLDL 10 µg/ml ß-VLDL 
FC 6.5 ± 0.7 7.5 ± 0.4 8.2 ± 0.6 
CE 0.6 ± 0.1 2.7 ± 0.1 2.6 ± 1.4 
TC 7.1 ± 0.7 10.2 ± 0.4 10.7 ± 0.8 
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5. Conclusion 
 
In this study we found higher ß-VLDL cell association in SR-BI overexpressing CHO 
cells compared to ldlA7 cells. There was still ß-VLDL cell association in ldlA7 cells, 
indicating the contribution of other receptors than the LDL-receptor and SR-BI to ß-
VLDL binding. Such possible binding sites could be LRP or ß-chain of ATPase that 
were both shown to mediate chylomicron uptake. 
 
ß-VLDL was utilized by the cells, as indicated by internalization and degradation of 
the particle over time. Furthermore, analyses of the cellular lipid pool after ß-VLDL 
feeding substantiate this finding. ß-VLDL derived lipid was delivered to the cells as 
shown by an increase in their cholesterol and cholesteryl ester content. 
 
Nevertheless, the LDL-receptor plays an important role in ß-VLDL metabolism as 
indicated by ~ 2-fold higher ß-VLDL cell association in LDL-receptor containing CHO 
cells compared to LDL-receptor lacking but SR-BI overexpressing ldlA7-SRBI cells. 
This is supported by results from SR-BI knockdown in HepG2 cells: diminished SR-BI 
expression did not decrease ß-VLDL cell association. 
 
 
We could show that SR-BI mediates the uptake and degradation of ß-VLDL particles 
in tissue culture. The role of SR-BI in the metabolism of particles containing apo-B 
might have an impact on arterial lesion development. 
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6. Abstract 
 
The present study was designed to elucidate the role of SR-BI in ß-VLDL 
metabolism. As SR-BI has recently been implicated in ß-VLDL uptake (Van Eck et 
al., 2007) it was of interest to further investigate the importance and characteristics of 
this process.  
The utilization of two different sets of cells, LDL-receptor positive HepG2 and CHO 
cells and LDL-receptor negative ldlA7 and ldlA7-SRBI cells, allowed an evaluation of 
the contribution of SR-BI and the LDL-receptor in ß-VLDL metabolism.  
Experiments illustrated that the majority of associated ß-VLDL is taken up by the cells 
and internalized particles can not be released back to the media, indicating an 
holoparticle uptake. 
We also found that SR-BI overexpression leads to a ~ 2-fold higher ß-VLDL cell 
association. The higher ß-VLDL association in CHO cells compared to ldlA7-SRBI 
cells provides evidence for the relative importance of the LDL-receptor. This is 
substantiated by the results from SR-BI knockdown in HepG2 cells, that did not 
impair ß-VLDL cell association. Former studies are in line with the present results 
concerning the importance of the LDL-receptor in ß-VLDL metabolism (Herijgers et 
al., 2000; Van Lenten et al., 1985; Perrey et al., 2001). 
ß-VLDL was utilized by the cells as indicated by an increase in the cellular lipid 
content (cholesterol, cholesteryl esters and triglycerides) after ß-VLDL feeding.  
The degradation of the particle was low but measurable, which is in accordance with 
former findings in macrophages (Tabas et al., 1990). 
In summary, SR-BI was shown to mediate the binding, uptake and degradation of ß-
VLDL particles in tissue culture. However, SR-BI seems to play a subsidiary role, as 
the LDL-receptor is particularly prominent in ß-VLDL metabolism, that might gain 
importance in cases where it compensates for defective pathways. 
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7. Zusammenfassung 
 
Das Ziel dieser Arbeit war, die Rolle von SR-BI im Stoffwechsel von ß-VLDL zu 
untersuchen. Da SR-BI kürzlich mit ß-VLDL Aufnahme in Verbindung gebracht wurde 
(Van Eck et al., 2007), war es von Interesse, die Wichtigkeit und Merkmale dieses 
Prozesses zu analysieren. 
Die Verwendung von zwei verschiedenen Zellsystemen, LDL-Rezeptor positive 
HepG2 and CHO Zellen und LDL-Rezeptor negative ldlA7 und ldlA7-SRBI Zellen, 
erlaubte eine Bewertung des Einflusses von SR-BI und des LDL-Rezeptors im 
Metabolismus von ß-VLDL. 
Die Experimente zeigten, dass die Mehrheit des assoziierten ß-VLDL von den Zellen 
aufgenommen wurde und dass die internalisierten Partikel nicht wieder von der Zelle 
abgegeben werden, was auf eine „Holopartikel“-Aufnahme hindeutet. 
Wir haben weiters herausgefunden, dass SR-BI Überexpression zu einer ~ 2-fach 
höheren ß-VLDL Zellassoziation führt. 
Die höhere ß-VLDL Assoziation in CHO Zellen verglichen mit ldlA7-SRBI Zellen 
untermauert die verhältnismäßige Wichtigkeit des LDL-Rezeptors. Diese wird 
bestätigt durch die Ergebnisse von SR-BI knockdown in HepG2 Zellen, welcher die 
ß-VLDL Assoziation nicht beeinträchtigt hat. Vorherige Studien entsprechen diesen 
Ergebnissen bezüglich der Wichtigkeit des LDL-Rezeptors im ß-VLDL Metabolismus. 
ß-VLDL wurde von den Zellen umgesetzt, was anhand des Anstiegs des zellulären 
Fettgehaltes (Cholesterin, Cholesterol Ester und Triglyceride) nach ß-VLDL Zufuhr 
gezeigt wurde. 
Die Abbaurate des Partikels war gering, aber messbar, was mit früheren 
Ergebnissen in Makrophagen übereinstimmt. 
Zusammenfassend kann gesagt werden, dass SR-BI die Bindung, Aufnahme und 
den Abbau von ß-VLDL in Zellkultursystemen vermittelt. Dennoch scheint SR-BI eine 
untergeordnete Funktion zu übernehmen, da der LDL-Rezeptor eine entscheidende 
Rolle im Metabolismus von ß-VLDL spielt, die aber an Wichtigkeit gewinnen könnte 
indem er beeinträchtigte pathways kompensiert. 
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